Bridgeway Capital Management LLC Acquires 47,293 Shares of Pfizer Inc. (NYSE:PFE)

Bridgeway Capital Management LLC grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 695,003 shares of the biopharmaceutical company's stock after purchasing an additional 47,293 shares during the quarter. Bridgeway Capital Management LLC's holdings in Pfizer were worth $18,438,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Pfizer during the 4th quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. bought a new position in Pfizer in the fourth quarter worth approximately $274,694,000. Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. raised its holdings in Pfizer by 1,106.0% during the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock valued at $143,967,000 after acquiring an additional 5,153,257 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.5 %

Shares of NYSE PFE traded down $0.10 during trading hours on Wednesday, hitting $22.78. The company had a trading volume of 48,160,808 shares, compared to its average volume of 40,426,421. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The stock has a market capitalization of $129.18 billion, a P/E ratio of 16.15, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The firm's 50 day moving average is $24.15 and its 200-day moving average is $25.65. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the business earned $0.82 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.55%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is 124.64%.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.